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Bile acids influence the growth, oestrogen receptor and oestrogen-regulated proteins of MCF-7 human breast cancer cells
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Summary The effects of the major human serum bile acid, glycochenodeoxycholic acid (GCDC), as well as unconjugated chenodeoxycholic acid (CDC), on the MCF-7 human breast cancer cell line have been studied in vitro under oestrogen and bile acid deprived culture conditions. GCDC increased the growth of the breast cancer cells over the range 10-300 jiM. At concentrations in excess of the bile acid binding capacity of the medium cell growth was prevented. In contrast 10 jiM CDC tended to reduce cell growth. Oestrogen (ER) and progesterone (PgR) receptors, pS2 and total cathepsin D were quantified by monoclonal antibody based immunoassays. Ten to 100 jiM GCDC and 10 jIM CDC down-regulated ER protein and this was accompanied by induction of the oestrogen-regulated proteins PgR, pS2 and possibly cathepsin D, including increased secretion of the latter two proteins into the culture medium. All these changes were quantitatively similar to those observed with 10 nm oestradiol. The bile acid effects on ER and PgR were not due to interference with the assay procedures. Cells incubated with 50 jIM GCDC or 10 jIM CDC had higher pmolar concentrations of the bile acids than controls. This study suggests that naturally occurring bile acids influence the growth and steroid receptor function of human breast cancer cells.
Although bile acids have been considered to play a role in the aetiology and/or growth of colorectal cancer (Hill, 1983) little attention has been paid to the possible activity of these steroidal compounds in breast cancer. Epidemiological studies have demonstrated that rates of breast and colon cancers are highly correlated with each other and with high fat and animal protein diets (Drasar & Irving, 1973). In the few studies published the data suggest that women with breast cancer may have differences in the faecal excretion of bile acids compared with controls; decreased (Murray et al., 1980) and increased (Papatestas et al., 1982) faecal concen- trations, and altered ratio of individual bile acids (Owen et al., 1986) have been reported. Long-term follow-up of women undergoing cholecystectomy has revealed an in- creased risk of breast cancer which increased with time after operation (Gudmundsson et al., 1989). In contrast, by reduc- ing the enterohepatic circulation of oestrogens and bile acids, the high consumption of fibre and fermented milk products, particularly in combination with low fat and animal protein intake, may provide some protection against breast cancer (Adlercreutz, 1990).
These findings, while by no means conclusive, imply that breast cancer patients are subject to changes in circulating levels of bile acids and consequently the potential exposure of breast tissue and/or tumour. In support of the latter possi- bility is our observation, now confirmed by others, that breast cyst fluid contains very high levels of bile acids, notably the glycine conjugates of chenodeoxycholic (CDC), deoxycholic and cholic acids (Baker et al., 1986 and 1988a; Raju et al., 1990).
Bile acids have been shown to produce DNA changes in murine lymphoblastoma cells and in yeast cells (Ferguson & Parry, 1984; Kulkarni et al., 1980). Several bile acids are mutagenic at non-toxic doses (Watabe & Bernstein, 1985), and have co-carcinogenic activity on a murine fibroblast cell line (Kawasumi et al., 1988).
The action of bile acids on human breast cancer cells has not previously been studied apart from our own preliminary reports (Baker et al., 1988b; Wilton et al., 1990). The
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predominant serum bile acid in healthy women and women with breast cancer is glycochenodeoxycholic acid (GCDC) (Baker et al., 1987). During tamoxifen treatment of elderly breast cancer patients the serum GCDC concentration is reduced while there is some increase in the unconjugated bile
acid fraction containing CDC (Baker et al., 1990). Perhaps complimentary to this latter observation are the lower levels
of unconjugated bile acids (cholic, CDC & deoxycholic) in the serum of women with oestrogen receptor (ER) rich
tumours and in healthy women taking oral contraceptive steroids continuously for over 6 years (Baker et al., 1987). We have therefore investigated the effects of GCDC and CDC on the human breast cancer cell line MCF-7, with particular emphasis on changes in ER and the oestrogen- regulated proteins progesterone receptor (PgR), pS2 and cathepsin D (Brown et al., 1984; Capony et al., 1989; Hor- witz et al., 1978; Johnson et al., 1989; Kida etal., 1989; May et al., 1989; May & Westley, 1988).
Methods
Materials
MCF-7 human breast cell lines were kindly provided by Dr R.E. Leake (Department of Biochemistry, University of Glasgow) and Dr A.E. Wakeling (ICI, Cheshire, England), and are identified as MCF-7(REL) and MCF-7(AEW) respectively. The sub-culture obtained from Dr Wakeling originated from cells supplied by the Glasgow laboratory. Culture media, supplements, NUNC plastic culture dishes and flasks, and mycoplasma free foetal calf serum (FCS) were obtained from Flow Laboratories (High Wycombe, Buckinghamshire, England), Gibco Ltd (Paisley, Scotland and Uxbridge, England), and Sigma Ltd (Poole, England). Human monocomponent insulin was from Novo Industri (Copenhagen, Denmark). Bile acids were of the highest available purity from Sigma and Calb'ochem (Bishops Stort- ford, England). Tamoxifen, 4-hydroxytamoxifen and ICI 164384 were kindly donated by ICI. Radiolabelled com- pounds were from Amersham International, England, and all other reagents were analytical grade, or the highest grade available, from Sigma or BDH (Atherstone, England or Hayman Ltd (Witham, England)). All aqueous reagent solu- tions and culture media were prepared with 0.22,um filtered ultra-pure water from a Milli-Q unit (Millipore, England) fed with water from a double-still or reverse osmosis unit.
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Dextran-coated charcoal treated FCS
Oestrogens and bile acids were removed from FCS by two or
three 1 h treatments at 56°C with dextran-coated charcoal
(DCC) (Horwitz et al., 1978). After the final centrifugation
step the FCS was passed through 0.22 gim sterile cellulose
acetate filters (Sartorius, England), which remove charcoal
fines, and checked for sterility on nutrient broth. The level of
residual 3H-oestradiol in DCC-treated FCS (DCC-FCS) was
< 1-2%. Residual oestradiol in DCC-FCS was undetectable
by RIA. The amount of residual '4C-glycocholic acid by the
above procedure was 1-3%. Radioimmunoassay (RIA) of
conjugated and unconjugated chenodeoxycholic acid (see
below) demonstrated that untreated FCS contained a
relatively high level of the bile acids (e.g. > 16 nmol ml-')
which was reduced to <3% in DCC-FCS. These observa-
tions indicate that the final concentration of the bile acids in
media containing 5% DCC-FCS was about 25 nM which
compares with the tLM concentrations of exogenous bile acids
used in this study. Approximately 80% ofendogenous insulin
in FCS was removed by the DCC procedure as assessed by
RIA (Incstar Corp, Minnesota, USA), whereas about 60% of
'4C-cholesterol remained in DCC-FCS.
Bile acid binding capacity ofFCS and DCC-FCS
A volume of DCC-FCS containing 100 yg albumin was
incubated with a saturating concentration (100 IM) of
glycocholic acid (GC) or chenodeoxycholic acid (CDC) con-
taining 100 nCi of '4C-labelled GC or CDC respectively in a
total volume of 1.0 ml of 10 mM phosphate buffer pH 7.4 for
3 h at 37°C with repeated mixing. Three 40 1tl aliquots of the
incubate were taken for counting (total radioactivity) and
800 tlI was passed through a YMT ultrafiltration membrane
in a MPS-1 unit (Amicon, Stonehouse, England) by centri-
fugation at 1,000 g for 10min. The resulting ultrafiltrate
(3 x 40pl) was added to 10 ml Scintran Cocktail T (BDH)
and the radioactivity counted (free or non-protein bound
activity). The amount of bound radioactivity was calculated
and used as an expression of bile acid binding capacity.
Cell culture procedures
Cells were grown at 37°C with 5% CO2 in air and were
maintained prior to experimentation in DME:Ham's F-10
(1:1) or DME media, both with phenol red, and containing
10% or 5% FCS and supplemented with glutamine (2mM),
penicillin (50 IU ml1), streptomycin (50 fig ml-') and
usually 1% non-essential amino acids (NEAA) and insulin
(1ltg ml'). For experimentation cells growing in log-phase
were transferred to phenol red free DME:Ham's F-12 (1:1)
medium containing 5% DCC-FCS and the above supple-
ments (experimental medium) in 24 well plates, 35 mm dishes
or flasks (75 or 80 cm2). In many cases cells were grown in
this medium for 7-14 days prior to addition of test agents.
For growth experiments cells were usually plated out in
triplicate into 35 mm petri dishes, while for the study of
receptors and proteins 75 or 80 cm2 flasks were used in order
to obtain sufficient numbers of cells. In these experiments
triplicate cultures were not set up for practical reasons, but
independent experiments were run on several separate
occasions. Each experiment within a series was performed
using newly cultured cells of the same passage number
obtained from liquid nitrogen storage. Bile acids, oestradiol
and antioestrogens were added to experimental medium in
ethanol (0.1% final concentration or less); controls received
the same amount of ethanol alone. These agents were added
in fresh medium when cells were plated out or 24 h later, and
then every 2-3 days when medium was changed. Cells were
harvested with trypsin/EDTA (Flow Laboratories) and
washed with medium and phosphate buffered saline (PBS)
prior to counting or homogenisation.
Cell counting
Intact cells were repeatedly passed through a plastic pipette
tip to obtain a single cell suspension and then counted on a
Coulter counter or with a haemocytometer. In later studies
cells were counted as nuclei using the method of Butler et al.,
1981.
Cell homogenisation
'Cytosol' preparation Harvested cells were washed several
times in PBS, suspended in 10 mM Tris buffer pH 7.4 con-
taining 1.0 mM EDTA, 15% glycerol and 0.25 mM dithio-
threitol (DTT) and homogenised on ice with an Ultra-Turrax
(model T 18/10, Sartorius, England) for 3 x 10 s at near
maximum speed. The supernatant obtained after centrifuga-
tion at 600g for 10min and 5,000g for 30 min at 4°C was
used as a 'cytosol' preparation for immediate assay of steroid
receptors. Cytosol prepared from this supernatant by centri-
fugation at 100,000g in a Beckman model L2-65B ultracen-
trifuge was shown to give very similar levels of ER by EIA
(see below) as the lower speed preparation (99 ± 15%,
n = 4).
'Whole cell' extraction For the later studies in which ER
and PgR were assayed in 'whole cell' extracts, harvested cells
were washed several times in PBS, suspended in 10 mM
HEPES buffer pH 7.4, containing 0.4 M KCI, 5 mM sodium
molybdate, 1.5 mM EDTA, 10% glycerol and 0.5 mM DTT
and homogenised as above. The supernatant after centrifuga-
tion at 2,000g for 10min and 5,000g for 30min at 4°C was
used for immediate assay of ER and PgR. Aliquots of the
extract as well as culture medium were stored at - 40°C for
other assays.
Steroid receptor assays
ER and PgR were determined in duplicate in 'cytosol' and
'whole cell' preparations with the enzyme immunoassays
(EIA) supplied by Abbott Diagnostics (Maidenhead, Eng-
land). Both the quality control (QC) material supplied with
the kits and an external QC supplied by the EORTC were
assayed with each batch of cell samples. Precision (CV%) of
the assays was as follows: ER< 100 fmol mg-', 4.8%
(n = 27), ER> I00 fmol mg', 5.0% (n = 64), PgR<O00 fmol
mg-', 6.0% (n = 23), PgR= 100-500fmolmg', 2.3% (n =
32), PgR> 500 fmol mg-1, 8.6% (n = 30).
pS2, Cathepsin D and GCDC assays
The oestrogen-regulated proteins pS2 and cathepsin D (52 kd
pro-cathepsin D plus the active enzyme) were determined
with the two site immunoradiometric assays (ELSA-PS2 and
ELSA-CATH-D) supplied by CIS (UK) Ltd. (High
Wycombe, England). Assays were performed in duplicate on
stored 'whole cell' extracts or culture medium diluted appro-
priately with the diluent provided in the kits. The high KCI
concentration of the homogenisation buffer had no effect on
the quantification of either protein (personal observation and
information from CIS). The CV for the pS2 assay was 5.4%
(n = 50) over the range 29-2,006 pg ml-' diluted sample.
For the cathepsin D assay the CV was 5.4% (n = 50) for
values < 1,000 fmol ml-' diluted sample and 10.7% (n = 50)
for values > 1,000 fmol ml1-I diluted sample.
GCDC and CDC in 'whole cell' extracts were quantified
with the same radioimmunoassay supplied by Farmos Diag-
nostica (Pharmacia Ltd, Milton Keynes, England) using the
kit procedure for serum which involves extraction into 95%
ethanol prior to assay. The CV was 8.6% (n = 29). This
assay was also performed on whole cells by dissolving the
washed (3 x) intact cell pellet in 1 ml 5% NaOH at 80°C for
1.5 h, diluting with 9 ml ofwater and extracting the bile acids
into methanol on a 100 mg Bondelut C18 solid phase cart-
ridge (Jones Chromatography, Hengoed, Wales). The dried
methanol extract was then extracted into 95% ethanol ready
for assay.568 P.R. BAKER et al.
Protein assay
Protein levels in cell preparations were determined using the
Bio-Rad protein assay with bovine serum albumin as stan-
dard.
Statistical analysis
Precision of an assay is expressed as the coefficient of varia-
tion (CV%) obtained from series of n duplicates. Results are
usually expressed as mean ± s.d. Statistical analysis was per-
formed by analysis of variance (AOV) with the Dunnett test
for multiple comparisons with control, or by paired t-test; the
5% level was considered to indicate a signficant difference.
Results
Bile acidbinding capacity ofDCC-FCS
The bile acid binding capacity of DCC-FCS in Jmol ml-'
undiluted serum was 2.4 ± 0.4 (n = 2) and 11.2 ± 0.3 (n = 4)
for GC and CDC respectively. From these values, the con-
centration of protein-bound bile acid in culture medium con-
taining 5% DCC-FCS would be 118 ± 20 gM for GC and
558 ± 16 .LM for CDC. Since bile acid binding to serum
albumin is a characteristic of the degree of hydroxylation of
the steroid nucleus rather than glycine conjugation (Lawrence
et al., 1980), these data suggest that medium containing 5%
DCC-FCS would have a GCDC protein binding capacity of
approximately 500 JIM.
Cell growth
Early studies were performed using MCF-7(REL) cells. The
effect of increasing concentration of GCDC on cell growth is
illustrated in Figure 1. Growth stimulation in this and other
similar experiments was clearly seen at concentrations of
GCDC between 10 and 300JIM, although above 100JIM
growth stimulation was not maintained after 8 days. Above
500 JIM GCDC was cytostatic, possibly because the protein
binding capacity of the medium was exceeded. At high con-
centrations (1 mM) GCDC was cytotoxic (data not shown).
Optimum growth stimulation appeared to occur at 100 JIM
GCDC and this produced significantly increased cell numbers
after 7 to 10 days of culture (25.0 ± 8.7 104 cells cm-2; con-
trol = 11.9 ± 4.0, P < 0.005, n = 7), and a significant
decrease in doubling time (1.8 ± 0.4 days; control = 2.6 + 0.4,
P <0.02, n = 4). This effect did not seem to depend on
'conditioning' of the cells in oestrogen and bile acid depleted
medium for 10 days prior to addition of GCDC. Preliminary
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Figure I Effect of different concentrations of GCDC on growth
of MCF-7(REL) cells. Cells were grown for 10 days in experi-
mental medium and then 6 x IO' cells were plated out into
35 mm dishes in 2 ml of fresh medium without (0) and with the
pM concentrations of GCDC shown in the figure. Medium was
changed every 2 days and intact cells were counted as described
under Methods. Doubling times (days) for log-phase of growth
for the GCDC concentration shown in parentheses were; 2.50 (0),
2.42 (0.5), 2.11 (1.0), 1.72 (10), 1.66 (50), 1.40 (100), 1.32 (200),
1.41 (300), 1.83 (500).
studies with a series of glycine conjugated and unconjugated
bile acids at 100 JIM suggests that at this concentration,
glycoursodeoxycholic, ursodeoxycholic and cholic acids have
little effect on cell growth, while glycolithocholic, lithocholic,
deoxycholic and CDC are cytotoxic, and glycine conjugates
of cholic, deoxycholic and CDC all stimulate cell growth.
Pre-conditioning cells in oestrogen and bile acid depleted
medium prior to experimentation was routinely performed
in subsequent studies with MCF-7 (AEW) cells. Although
this was done most commonly for 14 days the effects on
growth and steroid receptors seen with shorter times (2 or 7
days) were very similar and therefore results have been
combined. Lower concentrations of bile acids were used
in these experiments in an attempt to study more
physiological levels. In these experiments (n = 4-5) a
reduction in mean doubling time was seen for 10 nM oes-
tradiol (1.8 ± 0.4 days), 10 JIM GCDC (1.6 ± 0.2) and 50 JIM
GCDC (1.5 ± 0.1) compared with control (1.9 ± 0.2). These
differences were not significant on multiple comparisons
analysis (Dunnett test), although the effect of 50JLM GCDC
was significant (P <0.02) when compared with controls by
paired t-test. In three of four experiments 10J1M CDC
reduced cell growth giving a doubling time of 2.2 ± 0.5
days. The MCF-7(AEW) cells used in this study grew well
in the oestrogen and bile acid depleted medium containing
1 jIg ml-' human insulin, and the growth stimulation by
10 nM oestradiol was modest. In a separate series of
experiments cell doubling times were greatly reduced from
control (3.0 ± 0.2 days; n = 5) by 1 lIM tamoxifen
(5.8 ± 0.2) and 4-hydroxytamoxifen (6.1 ± 0.3), while
tamoxifen at 0.1JIM had little or no effect on cell prolifera-
tion.
Steroid receptors, pS2 and cathepsin D
Since concentrations of GCDC> 100JIM eventually resulted
in reduced cell growth (Figure 1) the effects of the bile acid
on these proteins were studied at 10-100JM. Cells were
harvested after 7 days culture without or with 10nM oes-
tradiol or bile acids. ER levels in 'cytosol' of MCF-7(REL)
cells were reduced by 10 nM oestradiol and 100 JM GCDC as
shown in Table I. In later experiments MCF-7(AEW) cells
were grown in oestrogen and bile acid depleted medium for 2
to 14 days prior to addition of lower, and more
physiological, levels of GCDC and CDC, and a similar
degree of down-regulation of ER in 'whole cell' extracts was
observed (Figure 2).
The down-regulation of ER by bile acids and oestradiol
was accompanied by significant induction of PgR and pS2 by
these agents in the same series of experiments (Figures 3 and
4). Furthermore, the substantial secretion of the latter pro-
tein into the culture medium observed in controls was greatly
increased by both bile acids (Table II). Although there
appeared to be some increase in the mean levels of total
cathepsin D (pmol mg-1) in these 'whole cell' extracts in
response to oestradiol (28 ± 10, n = 5), 10JIM GCDC
(29+14, n =4), 50JM GCDC (28 ± 19, n = 6) and CDC
(30 ± 9, n = 4), comparisons with controls (22 ± 13, n = 6)
did not reach significance. However, in the two experiments
in which cathepsin D was assayed in the medium 10 and
50JIM GCDC appeared to approximately double the secre-
tion of the protein (Table II).
Tamoxifen and 4-hydroxytamoxifen at 1 JlM increased ER
in 'whole cell' extracts relative to oestradiol stimulation
(327 ± 65%, n = 3; and 403 ± 57%, n = 2, respectively) and
decreased PgR (15 ± 3% and 13 ± 3%, respectively). On the
other hand, O.1I1M tamoxifen acted as an oestrogen, down-
regulating ER (58 ± 22% of control, n = 5) and inducing
PgR (344 ± 202% of control, n = 5) despite having little
effect on cell growth. ICI 164384 (0.1 JIM) reduced the levels
of both steroid receptors relative to oestradiol stimulation
(23 ± 5% and 1.3 ± 0.7%, n = 2, for ER and PgR respec-
tively) and this effect was partially reversed by 10nM oes-
tradiol. Tamoxifen at 0.1 JIM increased cellular cathepsin D
levels (40 ± 25 pmol mg-', n = 5) compared with control
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Table I Effect of oestradiol and 100gM GCDC on 'cytosol' ER levels of
MCF-7(REL) cells
fmolmg-' protein % of Control
Experiment Control E2 GCDC E2 GCDC
1 65 30 49 46 75
2 875 186 369 21 42
3 224 17 48 8 21
mean ± s.d. 25 ± 19 46 ± 27
fmol 10-6 cells % of Control
Experiment Control E2 GCDC E2 GCDC
1 10 7 7 70 70
2 97 39 36 40 37
3 58 3 10 5 17
mean ± s.d. 38±33 41 ±27
106 cells were plated out and grown in 20 ml experimental medium in
80 cm2 flasks for 7 days (late log-phase) without (Control) and with 10nM
oestradiol (E2) or 100t4M GCDC. Medium was changed every 2-3 days.
The results are for three independent experiments with newly cultured cells.
P<005 P <0.05 p <0.05 P<G0.01 P':0.0
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Figure 2 ER levels (fmol mg-' protein) in MCF-7(AEW) cells
grown in the presence of oestradiol, GCDC or CDC. Cells were
grown for 2 (one experiment), 7 (one experiment) or 14 (four
experiments) days in experimental medium before transfer to
75 cm2 flasks con'taining 15 ml of medium. After 24 h the medium
was replaced with fresh medium without (CTRL = Control) or
with 10 nM oestradiol (E2), 1IOlM GCDC (GCDC10), 5011M
GCDC (GCDC50) or 1OJLM CDC (CDC1O). Medium was changed
every 2-3 days. After 7 days (late log-phase) cells were harvested,
homogenised to prepare a 'whole cell' extract and assayed as
described under Methods. Results are expressed as mean (col-
umns) and s.d. (error bars) for the number of experiments shown
at the foot of each column. The P values above the columns are
for analysis using the Dunnett test for multiple comparisons with
CTRL (OAV gave P 0.011).
Figure 4 pS2 levels (ng mg-' protein) in MCF-7(AEW) cells
grown in the presence of oestradiol, GCDC or CDC. For details
see legend to Figure 2 and Methods. (AOV gave P = 0.0018).
(25 ± 13). At 1 !LM tamoxifen also increased cellular cathep-
sin D relative to control (204 ± 97%, n = 2) as well as the
amount secreted into the medium (253 ± 16%, n = 2). Inter-
estingly, 0.1 LM ICI 164384 increased cellular levels of
cathepsin D in two of three experiments but had little effect
on secretion of the proteinase into the culture medium. Very
low levels of secreted pS2 were obtained when cells were
grown for 6 days in medium without FCS (18 ± 9% of
control, n = 2). Antioestrogen effects on pS2 were not
studied.
P < 0.01 p < 0.01
I T P < 0.01 P < 0.01 I ~ ~ ~~I I'
E2
Figure 3 PgR levels (fmol mg-' protein) in MCF-7(AEW) cells
grown in the presence of oestradiol, GCDC or CDC. For details
see legend to Figure 2 and Methods. (AOV gave P = 0.0003).
Effect ofGCDC on assay ofER and PgR
'Whole cell' extracts of MCF-7(AEW) cells grown without
and with 10 nM oestradiol were mixed with varying concen-
trations of GCDC (0, 1, 5, 10, 50 and 100tLM final concen-
tration in cytosol) prior to assay of ER and PgR. Steroid
receptor values were generally unaffected by GCDC apart
from the high PgR levels induced by oestradiol where a 20%
decrease was seen at 50 and 100f4M GCDC. These concen-
trations are far in excess of the levels of bile acids detected in
cell extracts (see below). Over the concentration range
5-100 AM GCDC the recovery of the added bile acid from
the cytosol was 89 ± 8%.
GCDC and CDC in 'whole cell' extracts and whole cells
The 'whole cell' extracts in which oestrogen receptor and
regulated proteins were measured were assayed for GCDC/
CDC content by RIA. Control cells contained low levels of
the bile acids (2.5 ± 2.9 pmol 106cells) consistent with the
residual concentration of bile acids in the medium (24 nM).
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Table II Secretion of pS2 and cathepsin D by MCF-7(AEW) cells into the
culture medium in response to oestradiol, GCDC and CDC
Secreted pS2 (ng 10-6 cells 24 h-')
Experiment Control E2 GCDCIO GCDC50 CDCIO
2
3
4
46.3
10.0
30.6
60.2
150.9a 342.3 345.5
- 92.3 120.7
- - 107.2
- - 233.4
213.8
54.2
110.3
mean ± s.d. 36.8 ± 21.6 200.7 ± 109.6 126.1 ± 81.0
Secreted cathepsin D (pmol106 cells 72h-)
Experiment Control E2 GCDCIO GCDC50 CDCIO
1 1.25 1.68a 3.13 2.56 1.71
2 1.54 - 2.59 2.53 -
For experiments 1 and 2 (both proteins) cells were grown as described in
the legend to Figure 2 (7 or 14-day pre-conditioning) and 72 h medium was
collected after 7 days of culture when the cells were harvested. For
experiments 3 and 4 (pS2 only) 1-3 x 105 cells, pre-conditioned for 7 days,
were plated out and grown in 1 ml of experimental medium in 35 mm dishes
and 48 h medium after 6 days culture was assayed for pS2. (aThe effect of E2
on pS2 and cathepsin D secretion was only studied in one experiment).
While extracts of cells incubated with 10gM GCDC had
similar levels (3.8 ± 3.0), cells incubated with 50 JAM GCDC
(15.3+7.6, P<0.01, Dunnett test) or 1O1M CDC
(11.4 ± 3.6, P <0.05) contained significantly higher amounts
of bile acid. These latter results have been confirmed in
separate experiments in which whole cells, harvested every 2
days and processed as described above, had increasingly
higher levels of GCDC or CDC compared with controls; this
indicates that the cell-associated bile acid is not due to simple
cell adherence or residual medium. At 8 days the bile acid
levels of cells incubated with 10 JAM CDC and 50gM GCDC
were 17.0 ± 2.2 and 34.2 ± 1.4 pmol 10-6 cells (n = 2) respec-
tively compared with 1.8 ± 0.6 in controls.
Discussion
The most significant aspect of the present study is the
demonstration that GCDC and CDC appear to exert an
oestrogen-like effect on MCF-7 cells by down-regulating ER
levels and inducing the oestrogen regulated proteins PgR and
pS2, and possibly cathepsin D. The down-regulation of ER
was observed for both 'cytosol' and 'whole cell' levels of the
receptor which is localised to the nucleus in vivo (King &
Greene, 1984) from where it can be extracted into the soluble
supernatant by homogenisation with buffer containing 0.4 M
KCI (Saceda et al., 1988). Nevertheless, the decrease in
'cytosolic' ER by 100 JAM GCDC in early experiments was
similar to that seen in 'whole cell' extracts of cells exposed to
10-50 JAM GCDC and 1OJM CDC. The lower levels of bile
acids are within the range of post-prandial serum concentra-
tions (Beckett et al., 1981). The use of a monoclonal
antibody enzyme immunoassay (King & Greene, 1984) pro-
vided a very sensitive and precise method ofmeasuring recep-
tor protein, and the levels of ER in control cells and cells
treated with oestradiol observed here were very similar to
those in a previous study using the same assay kit (Saceda et
al., 1988). Furthermore, the decrease in ER protein after 7
days oestradiol treatment agrees well with the down-
regulation of ER mRNA after 2 days reported by others
(Berkenstam et al., 1989; Saceda et al., 1988). The present
study shows that the degree of down-regulation of ER by
10-1I100M GCDC and 1I0JM CDC was very similar to that
seen with 10 nM oestradiol.
The accompanying induction of PgR, pS2 and possibly
also cathepsin D by the two bile acids was also similar to
that seen with 10 nM oestradiol. The degree of oestradiol
induction of PgR mRNA and protein is reported to be 2-10-
and 3-20-fold respectively (Horwitz & McGuire, 1978;
Katzenellenbogen et al., 1987; Nardulli et al., 1988; Wei et
al., 1988), which is consistent with our data for oestradiol
and bile acids, although larger increases have been observed
(May et al., 1989; Read et al., 1988). The induction of PgR
by oestrogen appears to be due to changes at the transcrip-
tional, or possibly post-transcriptional, level, rather than
alteration of protein degradation (Read et al., 1988; Nardulli
et al., 1988; Wei et al., 1988), but whether this applies to bile
acids cannot be concluded from the present study. The effect
ofprogestins on bile acid-induced PgR levels might provide a
useful insight into this mechanism (Wei et al., 1988). ER and
PgR response to 0.1, 1 JAM tamoxifen (oestrogenic), 1 lJM
tamoxifen or 4-hydroxytamoxifen (antioestrogenic) and
ICI 164384 are consistent with previous reports of oestrogen-
responsive MCF-7 cells (Horwitz et al., 1978; Johnson et al.,
1989; May et al., 1989; Read et al., 1988).
The secreted protein pS2/pNR2 appears to be under
primary oestrogen control in breast tumours and cell lines,
but is also expressed by several epithelial tumours as well as
some normal tissues (Brown et al., 1984; Cavailles et al.,
1989; Henry et al., 1991; May & Westley, 1988). In addition
pS2, via activation of its enhancer element, is also induced by
insulin, IGF-I, bFGF, EGF, increased intracellular cAMP,
stimulation of protein kinase C (PKC) by phorbol esters and
some oncogene products (Cavailles et al., 1989; Nunez et al.,
1989). Many of these factors are known to mediate the
mitogenic activity of oestrogens, but the pS2 protein itself is
not a mitogen and its function is still unknown (Kida et al.,
1989). As well as inducing pS2, activation of PKC can result
in increased PgR levels (Sumida & Pasqualini, 1990). The
induction of pS2 and PgR by the bile acids was of the same
order as with the above agents, and it is possible that GCDC
and CDC act via similar mechanisms.
While the bile acids increased the secretion of cathepsin D
into the culture medium, the changes in cellular levels were
modest, as indeed was the case with oestradiol. Taken
together as a measure of the total increase in cathepsin D,
our, albeit limited data, suggest that some induction of
cathepsin D by bile acids occurred, but further studies are
required to confirm this including the use of cells in which
oestradiol significantly induces the protein. Cathepsin D is
expressed constitutively by ER + and ER - breast cancer
cells although it is regulated by oestrogens in the former
(Capony et al., 1989; May & Westley, 1988). It is induced by
many of the same factors that stimulate pS2 but not in-
creased cAMP or PKC activation (Cavailles et al., 1989). The
MCF-7 cells used here, although responding poorly to oes-BILE ACIDS AND MCF-7 HUMAN BREAST CANCER CELLS 571
tradiol, exhibited increased levels of cathepsin D in response
to tamoxifen as reported previously (Johnson et al., 1989).
There is some evidence that bile acids, including CDC and
deoxycholic acid (DC), can influence PKC activity, the direc-
tion of the effect being dependent on the concentrations of
calcium (Ca2") and phosphatidylserine (Fitzer et al., 1987).
Activation of PKC is involved in the DC-stimulated pro-
liferation of colonic epithelium, the bile acid probably acting
indirectly by stimulating polyphosphoinositide turnover
(Craven et al., 1987). Since at physiological concentrations
and pH CDC and DC, and their glycine conjugates, exhibit
high binding affinities for Ca2" (Gleeson et al., 1990), and
l1M concentrations of CDC and its monohydroxy metabolites
can release Ca2+ from intracellular stores and increase Ca2+
uptake in non-hepatic cells (Coquil et al., 1991; Oelberg et
al., 1990), bile acid interaction with Ca2" may represent a
potential mechanism for modulation of PKC activation.
Hypothetically, the observed effects of 1O-1I00 LM GCDC
and 10tMCDC could be due to a bile acid-mediated in-
crease in the bioavailability of residual oestrogens by dis-
placement of the latter from binding sites in FCS, and/or
increased membrane permeability to the steroid hormone.
While these possibilities require investigation, the current
data provide little support for such mechanisms. On the basis
of the procedure used to strip FCS, and the measurements
made to assess its efficiency (3H-oestradiol removal, RIA),
the concentration of residual oestrogen in the experimental
medium was considered to be extremely low and consistent
with published studies. It seems unlikely that the above levels
of bile acids, which are substantially below the binding
capacity of the medium, would displace oestrogens present at
low pmolar concentrations or less. Displacement of oestrogen
would be more likely at bile acid concentrations close to, or
higher than, the binding capacity, but cell proliferation was
lower at these levels, and GCDC induced a similar degree of
down-regulation of ER over a 10-fold concentration range.
Changes in membrane permeability might be expected at
high bile acid levels (Oelberg et al., 1990) but not with low
JAM quantities which are way below micellar concentrations
and detergent effects.
At relatively low concentrations, GCDC stimulated cell
growth in a dose response manner. This effect was observed
despite the fact that our MCF-7 cells grew well in the appar-
ent absence of oestrogens (and phenol red), even after a 14
day period of oestrogen deprivation prior to experimentation,
although human insulin at 1 tigml-' was always present in
the experimental medium. The growth characteristics of the
MCF-7 cell line does appear to depend on the particular
sub-clone used by different workers, some of which are not
totally oestrogen-dependent (Darbre & Daly, 1989;
Katzenellenbogen et al., 1987). Indeed the doubling time for
cells grown in 5% DCC-FCS and without phenol red for 1
week observed in the present study is very similar to that
reported previously (Katzenellenbogen et al., 1987). A steroid
memory effect may have been a contributory factor to the
basal cell growth (Darbre & Daly, 1989), although differences
in response between cells previously grown in the absence of
oestrogens for 14 days or for shorter periods were not seen.
The inhibition of cell proliferation by 1.OAM tamoxifen or
4-hydroxytamoxifen, and the lack of stimulatory effects of
0.1 JAM tamoxifen, are consistent with previous observations
in oestrogen unresponsive sub-clones of MCF-7 (Darbre &
Daly, 1989; Katzenellenbogen et al., 1987). It will be neces-
sary to study the effects of bile acids on cell proliferation, as
well as on oestrogen-regulated proteins, using different cell
lines that are clearly responsive or dependent on oestrogen
for growth. These matters apart, our data show that GCDC
appears to have a slightly more pronounced effect on the
growth of the MCF-7 cells used in the present study than
oestradiol. In contrast to the conjugated bile acid, CDC, and
possibly other unconjugated bile acids, appears to have either
little effect on cell growth or to reduce it, at least at concent-
rations above 10 JM. The absence of growth stimulation by
this bile acid is interesting in view of its effects on ER and
regulated proteins and requires further study.
The present study demonstrates that at high concentrations
GCDC is cytostatic, and eventually cytotoxic, to MCF-7
human breast cancer cells. The cytostatic/cytotoxic effect of
GCDC appears to be related to the capacity of the serum
containing medium to bind bile acids thereby limiting its
concentration in free solution. Although the serum binding
involves low affinity sites which do not affect the bioavail-
ability of the bile acids, the cytostatic/cytotoxic effects of
GCDC were only seen at concentrations in excess of the
binding capacity of the medium. Thus with medium contain-
ing 10% FCS inhibition of cell growth occurred at a higher
concentration than with 5% FCS (data not shown). This
suggests that bile acids in free solution, even below the
critical micellar concentration, interact with the cell
differently than when bound to serum proteins and/or lipo-
proteins. The latter may therefore be involved in bile acid
'uptake' by breast cancer cells.
Apart from the present report and our other preliminary
studies (Baker et al., 1991), the uptake of bile acids by breast
cancer cells has not been previously demonstrated. Although
bile acid uptake by breast cancer cells seems surprising, there
is increasing evidence that bile acids occur in extrahepatic
tissues (Dupont et al., 1988). Bile acids are probably largely
transported in the serum via lipoprotein (Dupont et al.,
1988), and a role for lipoproteins in the cellular uptake of
bile acids would be consistent with the observation that
breast cyst fluid contains high concentrations of non-
esterified cholesterol and HDL (Baker, 1990). The data pre-
sented do not indicate whether the bile acids are internalised
or bound to the plasma membrane surface. The observation
that control cells contained levels of bile acid similar to those
incubated with 10 IUM GCDC is consistent with a very slow
rate of bile acid uptake from residual bile acid in the experi-
mental medium and/or retention of bile acid taken up from
high concentrations in the maintenance medium which con-
tained unstripped FCS. We have observed prolonged reten-
tion of fluorescent bile acid analogues by human breast
cancer cells including MCF-7 cells (Wilton et al., 1990 and
unpublished observation). The relatively low levels of cell-
associated bile acid, particularly for cells incubated with
10 JM GCDC, might be expected if bile acids are taken up
via lipoproteins into which exogenously added bile acids are
not readily incorporated. On the other hand, a high extracel-
lular bile acid concentration may limit the rate of efflux of
bile acid already internalised or bound to the cell surface.
Incubation of cells with a 5-fold higher concentration of
GCDC produced, on average, a 5-fold higher bile acid level
in the cell extracts indicating that significant bile acid uptake
is dependent on a large concentration gradient. The higher
level of bile acid in cells incubated with 10JAM CDC suggests
that unconjugated bile acids enter or bind to the cell, or
become incorporated into lipoproteins, more readily than the
less hydrophobic glycine conjugates.
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